Rósula García‐Navas

This study shows that deleting both SOS1 and SOS2 in mice causes intestinal damage, bacterial leakage, and septicemia, but stemness-enhancing therapies improve survival.

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.